New drug aims to tame fatty liver disease in 3 months
NCT ID NCT03468556
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called SNP-610 for people with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. About 80 adults will receive either the drug or a placebo for 3 months. The main goal is to see if SNP-610 lowers liver enzyme levels and reduces liver fat.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASH - NONALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could estrogen patch reverse liver damage in postmenopausal women?
- Experimental drug aims to reverse liver scarring in NASH cirrhosis
- New drug HPG1860 shows promise in reducing liver fat in NASH patients
- Hope for NASH: new pill aims to reverse liver damage and prevent cirrhosis
- Sleeve gastrectomy vs. lifestyle: which tames fatty liver disease?
- Can a keto diet help obese patients with advanced liver disease?